Research Paper Volume 13, Issue 4 pp 5358—5368

The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE

Subgroup analyses of overall survival for HCC patients who underwent TACE according to various tumor characteristics. (A) Age≤60 years; (B) age>60 years; (C) HBV positive; (D) absence of viral hepatitis (E) AFP≤200 ng/ml, (F) AFP>200 ng/ml, (G) ALBI grade 1, (H) ALBI grade 2, (I) greatest tumor size≤5 cm, (J) greatest tumor size>5 cm, (K) absence of macroscopic vascular invasion; (L) presence of macroscopic vascular invasion, (M) absence of extrahepatic metastasis; (N) presence of extrahepatic metastasis; (O) BCLC stage A, (P) BCLC stage B, (Q) BCLC stage C.

Figure 2. Subgroup analyses of overall survival for HCC patients who underwent TACE according to various tumor characteristics. (A) Age≤60 years; (B) age>60 years; (C) HBV positive; (D) absence of viral hepatitis (E) AFP≤200 ng/ml, (F) AFP>200 ng/ml, (G) ALBI grade 1, (H) ALBI grade 2, (I) greatest tumor size≤5 cm, (J) greatest tumor size>5 cm, (K) absence of macroscopic vascular invasion; (L) presence of macroscopic vascular invasion, (M) absence of extrahepatic metastasis; (N) presence of extrahepatic metastasis; (O) BCLC stage A, (P) BCLC stage B, (Q) BCLC stage C.